Phase II Trial of Adjuvant Nivolumab Following Salvage Resection in Patients with Recurrent Squamous Cell Carcinoma of the Head and NeckJennifer L. Leddon, Trisha M. Wise‐Draper, Shuchi Gulati et al.|Clinical Cancer Research|2022Cited by 26
<i>BRAF</i> -V600E papillary thyroid cancer: Updated analysis of real-world patient data.Martina Chirra, Trisha M. Wise‐Draper, Lova Sun et al.|Journal of Clinical Oncology|2025Cited by 1
Data from Phase II Trial of Adjuvant Nivolumab Following Salvage Resection in Patients with Recurrent Squamous Cell Carcinoma of the Head and NeckJennifer L. Leddon, Trisha M. Wise‐Draper, Shuchi Gulati et al.|Unknown|2023Cited by 1
Genomic profiling and outcomes of BRAF V600E mutated papillary thyroid cancer.Hira Shaikh, Trisha M. Wise‐Draper, Julie McGrath et al.|Journal of Clinical Oncology|2022Cited by 1
Supplementary Table from Phase II Trial of Adjuvant Nivolumab Following Salvage Resection in Patients with Recurrent Squamous Cell Carcinoma of the Head and NeckJennifer L. Leddon, Trisha M. Wise‐Draper, Shuchi Gulati et al.|Unknown|2023Cited by 0